NT-proBNP Mediates the Association Between FGF23 and All-Cause Mortality in Individuals With Type 2 Diabetes

被引:0
作者
van der Vaart, Amarens [1 ,2 ,3 ]
Bakker, Stephan J. L. [2 ]
Laverman, Gozewijn D. [4 ]
van Dijk, Peter R. [3 ]
de Borst, Martin H. [2 ]
机构
[1] Univ Groningen, Univ Med Ctr Groningen, Dept Internal Med, Div Nephrol, POB 30-001, NL-9700 RB Groningen, Netherlands
[2] Univ Groningen, Univ Med Ctr Groningen, Dept Internal Med, Div Nephrol, Groningen, Netherlands
[3] Univ Groningen, Univ Med Ctr Groningen, Dept Internal Med, Div Endocrinol, Groningen, Netherlands
[4] Ziekenhuisgrp Twente, Div Nephrol, Dept Internal Med, Hengelo, Netherlands
来源
JOURNAL OF THE AMERICAN HEART ASSOCIATION | 2023年 / 12卷 / 23期
关键词
FGF23; NT-proBNP; type; 2; diabetes; volume homeostasis; GROWTH-FACTOR; 23; HEART; FGF-23;
D O I
10.1161/JAHA.123.031873
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: FGF23 (fibroblast growth factor 23) is associated with a higher mortality risk in type 2 diabetes, but the mechanism is unclear. We aimed to study whether NT-proBNP (N-terminal pro-brain natriuretic peptide) mediates the association between FGF23 and mortality.Methods and results: We analyzed C-terminal FGF23 and NT-proBNP levels in 399 patients with type 2 diabetes. Cox regression analyses were performed, followed by mediation analyses using Structural Equation Modeling. During follow-up of 9.2 [7.6-11.3] years, 117 individuals died. FGF23 was associated with all-cause mortality, independent of potential confounders (fully adjusted hazard ratio [HR], 2.32 [95% CI, 1.21-4.43], P=0.01). The association was lost upon further adjustment for NT-proBNP (HR, 1.84; 95% CI, 0.91-3.73). NT-proBNP accounted for 26% of the mediation effect between FGF23 and all-cause mortality.Conclusions: These findings suggest that a higher FGF23 level is associated with increased mortality in individuals with type 2 diabetes through an effect on volume homeostasis.
引用
收藏
页数:5
相关论文
共 18 条
  • [11] Mediation analysis with a time-to-event outcome: a review of use and reporting in healthcare research
    Lapointe-Shaw, Lauren
    Bouck, Zachary
    Howell, Nicholas A.
    Lange, Theis
    Orchanian-Cheff, Ani
    Austin, Peter C.
    Ivers, Noah M.
    Redelmeier, Donald A.
    Bell, Chaim M.
    [J]. BMC MEDICAL RESEARCH METHODOLOGY, 2018, 18
  • [12] Fibroblast growth factor 23 is not associated with and does not induce arterial calcification
    Scialla, Julia J.
    Lau, Wei Ling
    Reilly, Muredach P.
    Isakova, Tamara
    Yang, Hsueh-Ying
    Crouthamel, Matthew H.
    Chavkin, Nicholas W.
    Rahman, Mahboob
    Wahl, Patricia
    Amaral, Ansel P.
    Hamano, Takayuki
    Master, Stephen R.
    Nessel, Lisa
    Chai, Boyang
    Xie, Dawei
    Kallem, Radhakrishna R.
    Chen, Jing
    Lash, James P.
    Kusek, John W.
    Budoff, Matthew J.
    Giachelli, Cecilia M.
    Wolf, Myles
    [J]. KIDNEY INTERNATIONAL, 2013, 83 (06) : 1159 - 1168
  • [13] FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa
    Shimada, T
    Urakawa, I
    Yamazaki, Y
    Hasegawa, H
    Hino, R
    Yoneya, T
    Takeuchi, Y
    Fujita, T
    Fukumoto, S
    Yamashita, T
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2004, 314 (02) : 409 - 414
  • [14] FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis
    Shimada, T
    Hasegawa, H
    Yamazaki, Y
    Muto, T
    Hino, R
    Takeuchi, Y
    Fujita, T
    Nakahara, K
    Fukumoto, S
    Yamashita, T
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2004, 19 (03) : 429 - 435
  • [15] Fibroblast growth factor 23 is related to profiles indicating volume overload, poor therapy optimization and prognosis in patients with new-onset and worsening heart failure
    ter Maaten, Jozine M.
    Voors, Adriaan A.
    Damman, Kevin
    van der Meer, Peter
    Anker, Stefan D.
    Cleland, John G.
    Dickstein, Kenneth
    Filippatos, Gerasimos
    van der Harst, Pim
    Hillege, Hans L.
    Lang, Chim C.
    Metra, Marco
    Navis, Gerjan
    Ng, Leong
    Ouwerkerk, Wouter
    Ponikowski, Piotr
    Samani, Nilesh J.
    van Veldhuisen, Dirk J.
    Zannad, Faiez
    Zwinderman, Aeilko H.
    de Borst, Martin H.
    [J]. INTERNATIONAL JOURNAL OF CARDIOLOGY, 2018, 253 : 84 - 90
  • [16] Diastolic stiffness of the failing diabetic heart -: Importance of fibrosis, advanced glycation end products, and myocyte resting tension
    van Heerebeek, Loek
    Hamdani, Nazha
    Handoko, M. Louis
    Falcao-Pires, Ines
    Musters, Rene J.
    Kupreishvili, Koba
    Ijsselmuiden, Alexander J. J.
    Schalkwijk, Casper G.
    Bronzwaer, Jean G. F.
    Diamant, Michaela
    Borbely, Attila
    Van der Velden, Jolanda
    Stienen, Ger J. M.
    Laarman, Gerrit J.
    Niessen, Hans W. M.
    Paulus, Walter J.
    [J]. CIRCULATION, 2008, 117 (01) : 43 - 51
  • [17] Diabetes status-related differences in risk factors and mediators of heart failure in the general population: results from the MORGAM/BiomarCaRE consortium
    Vuori, Matti A.
    Reinikainen, Jaakko
    Soderberg, Stefan
    Bergdahl, Ellinor
    Jousilahti, Pekka
    Tunstall-Pedoe, Hugh
    Zeller, Tanja
    Westermann, Dirk
    Sans, Susana
    Linneberg, Allan
    Iacoviello, Licia
    Costanzo, Simona
    Salomaa, Veikko
    Blankenberg, Stefan
    Kuulasmaa, Kari
    Niiranen, Teemu J.
    [J]. CARDIOVASCULAR DIABETOLOGY, 2021, 20 (01)
  • [18] Fibroblast Growth Factor 23 and Adverse Clinical Outcomes in Type 2 Diabetes: a Bitter-Sweet Symphony
    Yeung, Stanley M. H.
    Bakker, Stephan J. L.
    Laverman, Gozewijn D.
    De Borst, Martin H.
    [J]. CURRENT DIABETES REPORTS, 2020, 20 (10)